
Today, Recursion announced that it has aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an investigational oral MEK1/2 inhibitor for the treatment of familial adenomatous polyposis (FAP). FAP is a rare, inherited disease that affects more than 50,000 patients in the US and EU5. Colectomy does not end the disease. Patients face lifelong endoscopic surveillance, repeated polyp removal and, for some, further major surgery. REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion’s AI foundation models. Recursion achieved a key regulatory milestone with FDA alignment on a composite event-free survival primary endpoint that includes a novel, clinically meaningful component: excision of an adenoma ≥10 mm throughout the GI tract will count as an event. This is of particular importance because adenomas of this size are associated with an increased risk of high-grade dysplasia and cancer. They occur regularly over the course of the disease in both the upper and lower GI tract. By counting qualifying excisions in either region as events, the primary endpoint captures a common and consequential intervention across FAP care. Our Ph2 TUPELO data gave us a strong foundation for our discussions. Presented at CGA-IGC on November 2, 2026, nearly 1 in 2 patients in the upper GI achieved polyp burden reductions of 65% or more, and two patients achieved reductions of 98% or more in the upper GI. No new safety signals were observed. The trial is expected to enroll approximately 200 adults with FAP following colectomy or proctocolectomy and is on track to begin in the second half of 2027. Full release: ir.recursion.com/news-releas… #RareDisease #FAP #AIDrugDiscovery





